Momenta Pharmaceuticals (NASDAQ:MNTA) and Harpoon Therapeutics (NASDAQ:HARP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Earnings and Valuation
This table compares Momenta Pharmaceuticals and Harpoon Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Momenta Pharmaceuticals||$23.87 million||139.09||-$290.05 million||($3.03)||-9.34|
|Harpoon Therapeutics||$5.78 million||52.09||-$55.57 million||($2.55)||-4.73|
Harpoon Therapeutics has lower revenue, but higher earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Momenta Pharmaceuticals and Harpoon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Momenta Pharmaceuticals and Harpoon Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Momenta Pharmaceuticals currently has a consensus price target of $37.25, indicating a potential upside of 31.58%. Harpoon Therapeutics has a consensus price target of $26.33, indicating a potential upside of 118.17%. Given Harpoon Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Harpoon Therapeutics is more favorable than Momenta Pharmaceuticals.
Insider & Institutional Ownership
97.0% of Momenta Pharmaceuticals shares are held by institutional investors. Comparatively, 75.5% of Harpoon Therapeutics shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Harpoon Therapeutics beats Momenta Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.